Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma
The aim of this study was to evaluate the therapy effect of thalidomide in the 4T1 murine mammary carcinoma. 4T1 cell suspension was injected into the posterior left flank of all animals to obtain solid tumors. Five days after inoculation, the treatment group was orally administered 150 mg/kg of thalidomide for seven days. Tumors were measured every 48 hours until the end of treatment. Whole blood was collected for hematology analysis. Our results suggest that thalidomide therapy increase the number of circulating leukocytes in the 4T1 murine mammary carcinoma, and this response is accompanied by a decrease in tumor growth.
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Digital revista |
| Langue: | English |
| Publié: |
Sociedade Brasileira de Patologia Clínica
2014
|
| Accès en ligne: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442014000100064 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| id |
oai:scielo:S1676-24442014000100064 |
|---|---|
| record_format |
ojs |
| spelling |
oai:scielo:S1676-244420140001000642014-03-31Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinomaReis,Diego Carlos dosSouza,Cristina Maria deCampos,Liliane CunhaSilva,Ana Cândida Araújo eLopes,Miriam Teresa PazCassali,Geovanni DantasFerreira,Enio mice neoplasia 4T1 tumor thalidomide The aim of this study was to evaluate the therapy effect of thalidomide in the 4T1 murine mammary carcinoma. 4T1 cell suspension was injected into the posterior left flank of all animals to obtain solid tumors. Five days after inoculation, the treatment group was orally administered 150 mg/kg of thalidomide for seven days. Tumors were measured every 48 hours until the end of treatment. Whole blood was collected for hematology analysis. Our results suggest that thalidomide therapy increase the number of circulating leukocytes in the 4T1 murine mammary carcinoma, and this response is accompanied by a decrease in tumor growth.info:eu-repo/semantics/openAccessSociedade Brasileira de Patologia Clínica Jornal Brasileiro de Patologia e Medicina Laboratorial v.50 n.1 20142014-02-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442014000100064en10.1590/S1676-24442014000100009 |
| institution |
SCIELO |
| collection |
OJS |
| country |
Brasil |
| countrycode |
BR |
| component |
Revista |
| access |
En linea |
| databasecode |
rev-scielo-br |
| tag |
revista |
| region |
America del Sur |
| libraryname |
SciELO |
| language |
English |
| format |
Digital |
| author |
Reis,Diego Carlos dos Souza,Cristina Maria de Campos,Liliane Cunha Silva,Ana Cândida Araújo e Lopes,Miriam Teresa Paz Cassali,Geovanni Dantas Ferreira,Enio |
| spellingShingle |
Reis,Diego Carlos dos Souza,Cristina Maria de Campos,Liliane Cunha Silva,Ana Cândida Araújo e Lopes,Miriam Teresa Paz Cassali,Geovanni Dantas Ferreira,Enio Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| author_facet |
Reis,Diego Carlos dos Souza,Cristina Maria de Campos,Liliane Cunha Silva,Ana Cândida Araújo e Lopes,Miriam Teresa Paz Cassali,Geovanni Dantas Ferreira,Enio |
| author_sort |
Reis,Diego Carlos dos |
| title |
Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| title_short |
Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| title_full |
Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| title_fullStr |
Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| title_full_unstemmed |
Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma |
| title_sort |
thalidomide promotes leukocytosis in mice inoculated with 4t1 mammary carcinoma |
| description |
The aim of this study was to evaluate the therapy effect of thalidomide in the 4T1 murine mammary carcinoma. 4T1 cell suspension was injected into the posterior left flank of all animals to obtain solid tumors. Five days after inoculation, the treatment group was orally administered 150 mg/kg of thalidomide for seven days. Tumors were measured every 48 hours until the end of treatment. Whole blood was collected for hematology analysis. Our results suggest that thalidomide therapy increase the number of circulating leukocytes in the 4T1 murine mammary carcinoma, and this response is accompanied by a decrease in tumor growth. |
| publisher |
Sociedade Brasileira de Patologia Clínica |
| publishDate |
2014 |
| url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442014000100064 |
| work_keys_str_mv |
AT reisdiegocarlosdos thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT souzacristinamariade thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT camposlilianecunha thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT silvaanacandidaaraujoe thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT lopesmiriamteresapaz thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT cassaligeovannidantas thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma AT ferreiraenio thalidomidepromotesleukocytosisinmiceinoculatedwith4t1mammarycarcinoma |
| _version_ |
1756427500551929856 |